Enliven’s loss grows as drug trials progress

BOULDER —  Enliven Therapeutics Inc., a Boulder-based, pre-revenue oncology drug developer that went public this year with a merger with Boston pharmaceutical company Imara Inc., saw its net loss increase in the first quarter of 2023 as its research and development and drug trials progress.

The company reported a net loss of $14.7 million for the most-recent period, compared with a net loss of $8.7 million in the first quarter of 2022.

“2023 is off to a strong start with the successful completion of our merger with Imara Inc. and the concurrent private financing, dosing of the first patient in the…